T. Rowe Price Associates’s Interpace Biosciences, Inc. Common Stock IDXG Stock Holding History

T. Rowe Price Associates’s Portfolio IDXG Stock Details IDXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-420	Closed	-$11K	–	2546
2016 Q1	$11K	Hold	420	–	–	﹤0.01%	2498
2015 Q4	$21K	Hold	420	–	–	﹤0.01%	2503
2015 Q3	$75K	Buy	420 +20	+5%	+$3.94K	﹤0.01%	2442
2015 Q2	$57K	Hold	400	–	–	﹤0.01%	2497
2015 Q1	$54K	Hold	400	–	–	﹤0.01%	2505
2014 Q4	$72K	Buy	400 +196	+96%	+$34.9K	﹤0.01%	2503
2014 Q3	$49K	Hold	204	–	–	﹤0.01%	2521
2014 Q2	$89K	Buy	204 +5	+3%	+$2.31K	﹤0.01%	2469
2014 Q1	$91K	Hold	199	–	–	﹤0.01%	2441
2013 Q4	$96K	Hold	199	–	–	﹤0.01%	2410
2013 Q3	$96K	Hold	199	–	–	﹤0.01%	2390
2013 Q2	$94K	Buy	+199	New	+$90.2K	﹤0.01%	2352

Other funds holding IDXG

Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Ancora Advisors Cleveland, Ohio $4.7B AUM 19.05% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return

Glenmede Trust Philadelphia, Pennsylvania $22.7B AUM

California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

T. Rowe Price Associates's IDXG Position: Q2 2016 in Review

T. Rowe Price Associates sold out of Interpace Biosciences, Inc. Common Stock (IDXG) in Q2 2016, closing a stake of 420 shares — an estimated $11K sold.

T. Rowe Price Associates first reported a position in IDXG in Q2 2013 and held it in 12 quarters. The position peaked at $96K in Q4 2013. 19 funds tracked by Wall St. Rank hold IDXG as of Q2 2016.

T. Rowe Price Associates reported no remaining Interpace Biosciences, Inc. Common Stock position as of Q2 2016 after selling out during the quarter.
T. Rowe Price Associates sold 420 Interpace Biosciences, Inc. Common Stock shares in Q2 2016, an estimated $11K.
T. Rowe Price Associates first reported a position in Interpace Biosciences, Inc. Common Stock in Q2 2013 and held it in 12 quarters.
T. Rowe Price Associates's Interpace Biosciences, Inc. Common Stock position peaked at $96K in Q4 2013.
19 funds tracked by Wall St. Rank held Interpace Biosciences, Inc. Common Stock as of Q2 2016.

Based on T. Rowe Price Associates's 13F filing for Q2 2016, filed 15 Aug 2016.